35 results about "Extended release tablets" patented technology

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

1.The name of the design product: packaging box (Alican Ning salted hydrochloric acid dimethyl aniline sustained-release tablet). 2.The use of the design product: used for the outer packaging of medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design contains colors.

The application provides a bupropion hydrochloride sustained-release tablet and a preparation method, and belongs to the technical field of pharmacy. The pharmaceutical composition contains 150 parts of bupropion hydrochloride, 122.5-157.5 parts of glycerin monostearate, 17.5-22.5 parts of triethyl citrate, 68-104 parts of microcrystalline cellulose and 2-6 parts of magnesium stearate, wherein the bupropion hydrochloride raw material and the glycerin monostearate and the triethyl citrate are prepared into a solid dispersion through a hot melt extrusion process. The application provides a bupropion hydrochloride sustained-release tablet which is stable in drug release, slow in growth of related substances, does not need to be coated and can be taken and eaten, and a preparation method.

The invention discloses a method for preparing trazodone hydrochloride sustained-release tablets through a centrifugal granulation process. The method comprises the following steps: S1, crushing trazodone hydrochloride and sieving; s2, weighing trazodone hydrochloride, a sustained-release material and a filling agent according to the prescription dosage, adding the weighed materials into a centrifugal granulator for melting granulation at the granulation temperature of 90-100 DEG C, maintaining the temperature for mixing granulation, and cooling to room temperature for later use after the granulation is completed; s3, carrying out size stabilization on the granules, adding an adhesive, uniformly mixing, adding a lubricant, and uniformly mixing; the particles containing trazodone hydrochloride are obtained; and S4, tabletting the granules to obtain the trazodone hydrochloride sustained release tablets. The trazodone hydrochloride sustained-release tablet prepared by the method disclosed by the invention is high in hardness, low in friability and convenient to operate, and is more beneficial to product packaging, transportation and storage; the method adopts the centrifugal granulator, is more energy-saving and environment-friendly, and can greatly reduce the cost of manpower and material resources; the preparation method disclosed by the invention is good in reproducibility, is more beneficial to commercial production, and brings greater benefits to enterprises.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The application discloses a dapagliflozin metformin sustained-release tablet, which comprises the following components: metformin hydrochloride, an isolation material, dapagliflozin propylene glycol monohydrate, a cosolvent, a lubricant, a diluent and a disintegrant. 90 The metformin hydrochloride is composed of three kinds of particles with different particle sizes, and the particle sizes D 90 of the three kinds of particles are 0.5-1.0 μm, 50-200 μm and 300-600 μm respectively. The weight composition ratio of the three kinds of particles is (0.5-1) : 1 : (0.5-1). The dapagliflozin metformin sustained-release tablet provided by the application has a longer action time, and can be uniformly and slowly released and chemically stable.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The application discloses a sitagliptin and metformin sustained-release tablet and a preparation process thereof, and belongs to the technical field of medicines.A sitagliptin and metformin sustained-release tablet comprises the following components in percentage by weight: 30-35% of coated sitagliptin microcapsules, 58-62% of metformin granules, 5-10% of outer layer disintegrating agents and 0.5-1% of lubricants.The coated sitagliptin microcapsules, the metformin granules, the outer layer disintegrating agents and the lubricants are mixed first, and then tableting is carried out, so that the sitagliptin and metformin sustained-release tablet is obtained.The sitagliptin and metformin sustained-release tablet provided by the application has excellent moisture resistance and stability, and can guarantee the quality and curative effect of medicines.

The application provides a method for simultaneously determining the content of dapagliflozin and metformin, which adopts a reverse-phase high performance liquid chromatography method to separate and determine the content of dapagliflozin and metformin in dapagliflozin and metformin sustained-release tablets. The method has good separation degree, solvent does not interfere with detection, and good method specificity. The detection method is simple, rapid, accurate, high in sensitivity, good in repeatability and accuracy, can quickly and accurately perform qualitative and quantitative analysis on the content of dapagliflozin and metformin hydrochloride in dapagliflozin and metformin sustained-release tablets, and ensures the controllability of the quality of the product.

The present application belongs to the field of medicine processing, and relates to a sustained-release tablet containing trazodone hydrochloride and a preparation method thereof. The sustained-release tablet is prepared from the following raw materials in parts by mass: 75-150 parts of active ingredient, 42-84 parts of filling agent, 12-24 parts of binding agent, 12-24 parts of release retardant, 3-6 parts of lubricant and wetting agent; the active ingredient is trazodone hydrochloride; the filling agent is one or more of sucrose, corn starch, lactose and microcrystalline cellulose; the binding agent is one or more of povidone K30, povidone K90 and hypromellose; the release retardant is one of Brazil palm wax, insect wax and lanolin; the lubricant is one or more of magnesium stearate, talc and silicon dioxide; and the wetting agent is one of purified water, 10% ethanol solution and propylene glycol solution. The method can solve the problem of particle caking and improve the dissolution behavior of the preparation.

This invention relates to a dapagliflozin-metformin extended-release tablet, which comprises a metformin hydrochloride tablet layer, a dapagliflozin tablet layer, and a gastrointestinal film coating. The metformin hydrochloride tablet layer contains 1000 mg of metformin hydrochloride, magnesium stearate, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose 2208, and silicon dioxide. The dapagliflozin tablet layer contains 5-25 mg of amorphous dapagliflozin, 6-15 mg of sodium carboxymethyl starch, anhydrous lactose, microcrystalline cellulose, magnesium stearate, and silicon dioxide. The extended-release tablet of this invention exhibits good stability under high temperature, high humidity, and light exposure. This invention also provides a method for preparing the dapagliflozin-metformin extended-release tablet.

The invention discloses an isosorbide dinitrate sustained-release tablet and a preparation method thereof, sodium alginate is used as a sustained-release skeleton, lactose, calcium hydrophosphate and dextrin are used as filling agents, and the hydrophilicity of lactose is beneficial for water to rapidly permeate into the tablet to start medicine dissolution; the hydrophobic and rigid structure of the calcium hydrophosphate hinders rapid penetration of water and drug diffusion; partial dissolvability of dextrin can form local corrosion or channels; through combination of multiple aspects, the permeation rate and diffusion path of moisture and the corrosion / expansion degree of a tablet matrix can be adjusted, a more controllable and more stable drug release environment is constructed together, and the sustained release requirement is met.

The phencynonate hydrochloride sustained release tablet comprises the following components: phencynonate hydrochloride, a sustained release material, dodecanal, a 40% dimethylamine aqueous solution, sodium triacetoxyborohydride, an adhesive, a filler and a lubricant, the invention also relates to a preparation method of the phencynonate hydrochloride sustained release tablet. The sustained-release material is added to delay the release of the water-soluble phencynonyl hydrochloride, then lauric aldehyde and dimethylamine are further added to react in the presence of a reducing agent sodium triacetoxyborohydride to generate high-fat-solubility, low-toxicity and stable tertiary amine, and the tertiary amine and phencynonyl ester cations in the phencynonyl hydrochloride can form hydrophobic ion pairs; the release rate from the preparation to a water phase is slowed down, slow release of the medicine is realized, the action time is prolonged, the administration frequency is reduced, and the compliance to people taking vehicles for a long time is improved.

1. The name of the design product: medicine packaging box (sustained-release morphine hydrochloride tablets). 2. The use of the design product: medicine packaging box. 3. The design points of the design product: in the pattern. 4. The picture or photo that best indicates the design points: front view.

According to the trazodone hydrochloride sustained release tablet and the preparation method thereof, high-viscosity hydroxypropyl methylcellulose and low-viscosity hydroxypropyl methylcellulose are combined to serve as a sustained release material, the sustained release tablet can play a synergistic role to form a double-skeleton structure, so that medicine is stably released at a constant speed within 12-24 hours, and the sustained release effect is good. The sustained-release tablet can accurately regulate and control the drug release speed and reduce the fluctuation of blood concentration, so that the drug taking frequency is reduced to once a day, the risk of adverse reactions such as dizziness and drowsiness is reduced, the curative effect, compliance and safety of a patient are improved, and meanwhile, the sustained-release tablet is consistent in release behavior in different pH media, good in in-vivo absorption predictability and suitable for clinical application. Related substances grow slowly, the tablet stability is good, and the preparation method is simple, low in cost and suitable for industrial production.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and / or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

The invention discloses a sitagliptin and metformin sustained release tablet without an antioxidant as well as a preparation method and application of the sitagliptin and metformin sustained release tablet. Relates to the field of medicine preparation. The sitagliptin and metformin pharmaceutical composition without the antioxidant comprises a tablet core and a coating, the tablet core comprises a sitagliptin layer and a metformin layer which are laminated; the sitagliptin layer and the metformin layer contain drug release pore channels; the metformin layer is prepared from the following components: metformin and an expansion material. According to the invention, through the dual design of the coating and the drug release pore channel, the drug has oxidation resistance and the characteristic of rapid release of the sitagliptin drug at the same time, the sitagliptin is ensured not to be oxidized under the condition that an antioxidant is not used, and rapid release of the sitagliptin is further realized, so that the treatment effect of taking effect rapidly is achieved. And meanwhile, the slow-release treatment effect of the metformin medicine is also considered.

The application discloses a preparation method of a trazodone hydrochloride sustained-release tablet and a new tablet type. The sustained-release tablet is mainly composed of trazodone hydrochloride, a skeleton material, a pore forming agent, a binder and a lubricant and the like medicinal auxiliaries. In the application, a swing granulator is used to granulate and integrate the materials. The optimal aging condition of the trazodone hydrochloride sustained-release tablet is obtained through sample dissolution, the problems of high material loss and high equipment energy consumption in the prior art prepared by a fluidized bed are avoided, the tablet type is screened, the product stability is ensured, and the defect of high friability and easy breaking of the original research tablet type is avoided.

The application discloses a compound sustained-release tablet for treating diabetes and a preparation method thereof. The compound sustained-release tablet for treating diabetes comprises a dapagliflozin layer, a metformin sustained-release layer and a coating layer. The metformin sustained-release layer comprises a release modifier which is composed of hydroxypropyl methyl cellulose K4M and hydroxypropyl methyl cellulose K35M. Through screening and optimization of the selection and proportioning of a drug source, sustained-release materials and auxiliary agents, the two active components in the compound sustained-release tablet are released gently and durably, and the absorption of the drug is good.

The utility model discloses a kind of sustained-release tablets with anti-abuse function, comprising: first shielding layer, drug-containing layer and second shielding layer;The drug-containing layer has opposite top surface and bottom surface, and the side peripheral surface of connecting the top surface and bottom surface;The first shielding layer and the second shielding layer respectively cover the top surface and bottom surface of the drug-containing layer, jointly form the three-layer tablet core that the drug-containing layer is clamped in middle, and make the side peripheral surface of the drug-containing layer expose;Wherein, the drug-containing layer includes easily abused drug and pharmaceutically acceptable adjuvant, the first shielding layer and the second shielding layer are all high molecular material layer;And at least one sustained-release coating layer and gastric soluble coating layer that surface of the three-layer tablet core is successively coated;The easily abused drug includes hydrocodone bitartrate, oxycodone hydrochloride or hydromorphone hydrochloride.

This application relates to the field of pharmaceutical analysis technology and discloses a method for detecting the content and impurities of trazodone hydrochloride sustained-release tablets. This method can simultaneously determine the content of trazodone hydrochloride sustained-release tablets and its impurities using HPLC. The method has high specificity; blank solvents and blank excipients do not interfere with the retention times of the main peak and impurity peaks, and the separation between the main peak and each impurity is good. The method has good precision and reproducibility, and can be operated by different instruments and personnel. It has high accuracy and sensitivity, accurately detecting even low levels of impurities. It has good robustness; small variations in chromatographic conditions and solutions do not affect the detection results. Furthermore, because it can simultaneously detect content and related substances, it can significantly improve detection efficiency and save on manpower and material costs. This method uses isocratic elution, is simple to operate, and requires minimal instrumentation; a single pump can complete the analysis. The mobile phase conditions for isocratic elution are fixed, resulting in small baseline fluctuations and stable and reliable experimental results.

The application relates to the field of metformin hydrochloride sustained-release tablets, and discloses a metformin tablet pressing machine which comprises an operation table, a lower mold mechanism is slidably connected to the upper surface of the operation table, an upper mold mechanism is fixedly installed on the left side of the upper surface of the operation table and located on the left side of the lower mold mechanism, a discharging mechanism is fixedly installed on the left side of the upper surface of the operation table and located on the left side of the upper mold mechanism, and a feeding mechanism is fixedly installed on the right side of the upper surface of the operation table and located on the right side of the lower mold mechanism. The lower mold mechanism and the auxiliary plate are arranged, the formed tablets can be separated from the lower mold mechanism, the tablets formed on the lower mold mechanism can be effectively scraped off from the lower mold mechanism, the subsequent collection work is facilitated, the upper mold mechanism can effectively extrude and form the medicine raw materials on the lower mold mechanism.

The application discloses a raw material smashing device for metformin hydrochloride sustained-release tablet production and relates to the technical field of smashing processing. The raw material smashing device comprises a smashing assembly which is used for smashing raw materials, and a fixing assembly and a pre-installation assembly are arranged in the smashing assembly. When the raw material smashing device is used, the smashing hammer is pre-installed through the pre-installation assembly, a hydraulic rod is started, a moving rod is pulled to move to the left side, the fixed plate and the fixed rod are driven to move together, the L-shaped rod is in contact with the fixed plate on the right side, the L-shaped rod is driven to be inserted into the clamping hole, the fixed plate on the right side limits the L-shaped rod, the L-shaped rod limits the connecting rod, the smashing hammer is limited, and multiple hammer heads are quickly installed and fixed under the cooperation of the fixing assembly and the pre-installation assembly, so that the bolts are not required to be installed one by one, the bolts are prevented from being loosened and falling off due to impact force, and the hammer heads are prevented from being loosened.

1. The name of the design product: packaging box (oxycodone hydrochloride sustained-release tablets). 2. The use of the design product: packaging of pharmaceuticals. 3. The design points of the design product: in the pattern. 4. The picture or photo that best indicates the design points: front view.

The invention relates to the field of tablet preparation, and discloses a dapagliflozin and metformin sustained release tablet preparation method and equipment thereof.The dapagliflozin and metformin sustained release tablet preparation equipment comprises a bottom plate, the left side surface of the bottom plate is fixedly connected with a drying barrel, the right side surface of the bottom plate is fixedly connected with a placement seat, and the inner side wall of the drying barrel is provided with a multidirectional drying quantification mechanism; and the multidirectional drying and quantifying mechanism is used for quantitatively adding the mixed dapagliflozin and metformin sustained release tablet powder raw materials into a drying barrel to be fully dried, so that moisture and condensation are avoided. The hot air blown out by the double-end blowing seat is divided into two paths, one path penetrates through the ventilation plate to suspend the raw materials, and is matched with the annular airflow channel of the lower air inlet and the upper air blowing opening in the side wall of the drying barrel to form multi-directional hot air circulation of bottom upward blowing and side wall annular blowing; and drying dead angles on the barrel wall and the top are thoroughly eliminated.

The utility model discloses a metformin hydrochloride sustained-release tablet stamping die, which relates to the technical field of medicine processing dies and comprises a bottom limiting plate, a fixing plate is slidably mounted on the upper surface of the bottom limiting plate, and a top plate is slidably mounted on the lower surface of the bottom limiting plate; a plurality of bottom molds are uniformly arranged on the inner side of the fixing plate at intervals, and a top limiting plate is slidably mounted on the upper surface of the fixing plate; a plurality of push plate components are respectively arranged on the inner sides of the plurality of bottom molds; a plurality of top molds are evenly arranged on the lower surface of the top limiting plate at intervals, and a plurality of fastening screws are evenly arranged on the upper surface of the top limiting plate at intervals. By means of the structure, the bottom mold and the top mold which are abraded can be rapidly replaced and maintained, the situation that the whole mold is replaced is avoided, maintenance and production cost is reduced, tablets can be rapidly ejected out, and production efficiency is improved.

An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.

The invention discloses a trazodone sustained-release tablet and a preparation method thereof, and belongs to the field of pharmaceutical preparations, and the sustained-release tablet contains trazodone hydrochloride, a sustained-release framework material, a pore-foaming agent, an adhesive and other pharmaceutic adjuvants. The preparation method comprises the following steps: preparing sustained-release particles from trazodone hydrochloride, a skeleton sustained-release material and other necessary auxiliary materials by adopting a hot-melt extrusion granulation process, and then mixing and tabletting the sustained-release particles and the auxiliary materials to prepare the trazodone sustained-release tablet. The preparation process is simple, the production reproducibility is relatively good, the sustained release effect of the product is good, the release behavior of the product is relatively consistent with that of a foreign original sustained release preparation, and the problems that the original product is easy to break and high in friability are solved.

The utility model relates to the technical field of pharmaceutical production, concretely relates to a production equipment of metformin hydrochloride sustained-release tablet, including stirring mechanism and mixing subassembly, the stirring mechanism includes support frame, and the inner wall fixed connection of support frame has the cylinder, the inner wall fixed connection of support frame has the connecting frame, and the inner wall fixed mounting of connecting frame has the blanking assembly, the blanking assembly includes the blanking seat fixed connection on the connecting frame, and the inside of blanking seat is provided with the circular cavity, the inner wall of circular cavity is provided with feed port and discharge port respectively, the blanking seat is linked together through feed port and cylinder. The utility model overcomes the deficiency of prior art, through setting up blanking assembly between stirring mechanism and mixing subassembly, the cooperation between blanking assembly and motor, conveniently convey the smashing raw materials in the cylinder to the mixing cylinder, the blanking assembly can adjust the rate of raw material delivery, and then avoid the problem that raw materials appear to jam in the process of cylinder blanking.

This invention provides an utpatinib extended-release tablet composition and its preparation method. The extended-release tablet composition comprises 2-8% utpatinib, 50-70% filler, 15-25% controlled-release polymer, 10-25% pH adjuster, and other pharmaceutically acceptable excipients. The pH adjuster is a combination of tartaric acid and aspartic acid, and the utpatinib comprises a pharmaceutically acceptable salt thereof. The extended-release tablets of this invention utilize a specific combination of pH adjusters, particularly when combined with the active pharmaceutical ingredient, resulting in utpatinib extended-release tablets that not only maintain good dissolution, especially good long-term dissolution, but also have low levels of related substances and good quality stability.